课题基金 / 基金详情

DCTD Synthetic Chemistry

DCTD Synthetic Chemistry
DCTD合成化学
批准号:
7789121
负责人:
LARRY ARTHUR
金额:
$130.0万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-09-26 至 2018-09-25
关键词:

项目摘要

项目成果

LARRY ARTHUR的其他基金

相似基金

相关文献

中文摘要
翻译
合成化学实验室(LSC)的主要临床前目标是为发展治疗项目的癌症药物发现和开发工作以及DCTD-CCR (JDC)联合开发委员会批准的项目提供化学支持。为此,LSC将把其活动重点放在先导优化上,这是新药发现和开发的重要组成部分。将开发新的合成方法,以有效的先导化合物为基础创建新的类似物,以迭代的方式解决以下药物特性:活性、肿瘤选择性、溶解度、生物利用度、稳定性和ADME/PK,从而改善药物谱。该实验室正在开发新的有关综合方法,供更广泛的校外社区,特别是由发展和发展署资助的校外社区应用。
英文摘要
The Laboratory of Synthetic Chemistry (LSC) has been established with a primary preclinical objective to provide chemistry support to the cancer drug discovery and development efforts of the Developmental Therapeutics Program and the projects approved by the Joint Development Committee of DCTD-CCR (JDC). Towards this end LSC will focus its activities on lead optimization, an essential and integral part of new drug discovery and development. Novel synthetic methodologies will be developed to create new analogs based on the effective lead compounds to improve pharmaceutical profiles by addressing the following drug properties: activity, tumor selectivity, solubility, bioavailability, stability and ADME/PK in an iterative fashion. The laboratory is engaged in developing new relevant synthesis methodologies for applications by the wider extramural community, especially those funded by DCTD. Most recently, DCTD in conjunction with the Center for Cancer Research and the Office of the Director, NCI established a new program called the Chemical Biology Consortium (CBC) to facilitate the discovery and development of new agents to treat cancer. The CBC is expected to be an integrated research consortium at the cutting edge of chemical biology and molecular oncology that will work with various programs within NCI and outside scientific community, establish an iterative cancer drug discovery group on the scale of a small biotechnology concern, and advance new cancer therapy into the clinic. The goal of the CBC is to focus on unmet therapeutic needs in oncology that are not currently addressed by the private sector, including the pharmaceutical industry. To address this challenge and to re-establish NCI as a major player in the national cancer therapeutic arena, successful interaction of CBC Screening and Chemistry centers and other scientific groups is necessary. To achieve this goal, the LSC has become the CBC Chemistry support center that will interact with various DCTD centers and programs within NCI and outside contractor laboratories to facilitate the identification of new drug discoveries through medicinal chemistry with the ultimate goal of developing new clinical candidates.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Laboratory of Molecular Technology
Pathology/Histotechnology
Comp IT Program for Facilitating Drug Discovery & Development
DCTD Cancer Diagnosis
海外基金